Type I and II interferon signaling in colorectal cancer liver metastasis

Cytokine. 2023 Jan:161:156075. doi: 10.1016/j.cyto.2022.156075. Epub 2022 Oct 30.

Abstract

Metastatic colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Traditional chemotherapy extended the lifespan of cancer patients by only a few months, but targeted therapies and immunotherapy prolonged survival and led to long-term remissions in some cases. Type I and II interferons have direct pro-apoptotic and anti-proliferative effects on cancer cells and stimulate anti-cancer immunity. As a result, interferon production by cells in the tumor microenvironment is in the spotlight of immunotherapies as it affects the responses of anti-cancer immune cells. However, promoting effects of interferons on colorectal cancer metastasis have also been reported. Here we summarize our knowledge about pro- and anti-metastatic effects of type I and II interferons in colorectal cancer liver metastasis and discuss possible therapeutic implications.

Keywords: Colorectal cancer CRC; Colorectal cancer liver metastasis CRLM; Tumor microenvironment TME; Type I interferon; Type II interferon IFN-γ.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colorectal Neoplasms* / pathology
  • Humans
  • Immunotherapy
  • Interferons*
  • Liver Neoplasms* / secondary
  • Tumor Microenvironment

Substances

  • Interferons